Releviate Therapeutics

Steven P. Cohen, Chief of Pain Medicine at Johns Hopkins, Joins Releviate Therapeutics as Head of Its Scientific Advisory Board Cohen’s Appointment Comes on the Heels of Releviate Therapeutics Closing Series A Funding SAN DIEGO – July 27, 2021 – Releviate™ Therapeutics, a bio-pharmaceutical company developing a novel human antibody-based approach to treating neuropathic

Releviate Therapeutics Appoints Jennifer Maynard to Its Scientific Advisory Board As One of the Pharmaceutical Industry’s Leading Antibody Specialists, Maynard Brings Releviate Therapeutics Over 20 Years of Experience in Antibody Therapeutics SAN DIEGO – May 4, 2021 – Releviate™ Therapeutics, a bio-pharmaceutical company addressing the needs of patients suffering from neuropathic pain, today welcomes

Releviate Therapeutics Appoints Vyomesh Joshi to its Board of Directors The Seasoned Technology Executive Brings the Board Over 40 Years of Experience Driving Market Share Gains and Mission Critical Business Transformations SAN DIEGO – Jan. 05, 2021 – Releviate Therapeutics, a bio-pharmaceutical company addressing the needs of patients suffering from chronic pain, today welcomes

Founding Dean of UC San Diego Rady School of Business Joins Releviate Therapeutics’ Board of Directors Operations Management Veteran Robert Sullivan Brings Over 30 Years of Experience to Bio-Pharmaceutical Startup SAN DIEGO – Dec. 8, 2020 – Releviate Therapeutics, a bio-pharmaceutical company addressing the needs of patients suffering from chronic pain, today welcomes Robert

Releviate Therapeutics Inks Exclusive License for Human Monoclonal Antibodies for Chronic Pain Indications   Therapies Based on Extensive Neuropathic Pain Research Conducted at UC Riverside and Duke University Target Chronic Pain at Its Source: Matrix Metalloproteinases SAN DIEGO — Oct. 28, 2020 — Releviate™ Therapeutics, a bio-pharmaceutical company addressing the needs of patients suffering